What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)?

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best immunotherapy stocks to buy according to hedge funds. Bristol-Myers Squibb Company (NYSE:BMY) announced on February 12 plans to become an inaugural partner to Life Science Cares in support of its national campaign in fighting food insecurity. Management reported that the Food is Health: Nourishing Communities, Advancing Health initiative, led by Life Science Cares, aims to invest $30 million and mobilize 30,000 volunteer hours by 2030 to deliver a measurable and lasting impact for communities across the nation.

In another development, Bernstein reiterated its Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) on February 10 and set a price target of $58.00. Bristol-Myers Squibb Company (NYSE:BMY) also received a rating update from Morgan Stanley on February 6, which lifted the price target on the stock to $40 from $37 while keeping an Underweight rating on the shares. The firm told investors in a research note that while the 2026 revenue and EPS guidance exceeded consensus, it was driven by a higher-than-expected Eliquis guide.

The rating updates came after Bristol-Myers Squibb Company (NYSE:BMY) reported fiscal Q4 and full-year financial results for 2025, reporting a 1% growth in fiscal Q4 revenue to $12.5 billion, with growth portfolio revenue rising 16% to $7.4 billion. Full-year revenues reached $48.2 billion, and growth portfolio revenues increased 17% to $26.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including oncology, cardiovascular, immunology, and neuroscience.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.